TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07483099: A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT07483099 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07483099 Rescue Dossier →